KEROS THERAPEUTICS INC's ticker is KROS and the CUSIP is 492327101. A total of 125 filers reported holding KEROS THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $673,306 | -20.7% | 21,120 | 0.0% | 0.00% | – |
| Q2 2023 | $848,602 | +21.9% | 21,120 | +29.6% | 0.00% | – |
| Q1 2023 | $696,010 | -11.1% | 16,300 | 0.0% | 0.00% | – |
| Q4 2022 | $782,726 | +39.5% | 16,300 | +9.4% | 0.00% | – |
| Q3 2022 | $561,000 | +35.5% | 14,900 | -0.7% | 0.00% | – |
| Q2 2022 | $414,000 | -37.6% | 15,000 | +23.0% | 0.00% | – |
| Q1 2022 | $663,000 | -7.1% | 12,200 | 0.0% | 0.00% | – |
| Q4 2021 | $714,000 | +19.6% | 12,200 | -19.2% | 0.00% | – |
| Q3 2021 | $597,000 | -6.9% | 15,100 | 0.0% | 0.00% | – |
| Q2 2021 | $641,000 | -23.4% | 15,100 | +11.0% | 0.00% | – |
| Q1 2021 | $837,000 | -18.2% | 13,600 | -6.2% | 0.00% | – |
| Q4 2020 | $1,023,000 | +278.9% | 14,500 | +107.1% | 0.00% | – |
| Q3 2020 | $270,000 | +17.9% | 7,000 | +14.8% | 0.00% | – |
| Q2 2020 | $229,000 | – | 6,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,412,705 | $99,652,000 | 10.82% |
| CHI Advisors LLC | 433,852 | $30,604,000 | 8.62% |
| VR Adviser, LLC | 672,306 | $47,424,000 | 6.97% |
| Consonance Capital Management LP | 557,095 | $39,297,000 | 3.67% |
| Logos Global Management LP | 450,000 | $31,743,000 | 2.72% |
| RA Capital Management | 1,875,000 | $132,263,000 | 1.85% |
| Nantahala Capital Management | 534,514 | $37,705,000 | 1.17% |
| Orbimed Advisors | 1,679,417 | $118,466,000 | 1.04% |
| Eventide Asset Management | 346,000 | $24,407,000 | 0.37% |
| Atom Investors LP | 49,981 | $3,526,000 | 0.36% |